On the evening of March 28, Haohai Biotechnology (688366.SH) released its 2021 annual report. During the reporting period, the company achieved operating income of 1.667 billion yuan, a year-on-year increase of 32.61%; net profit attributable to the parent company of 352 million yuan, a year-on-year increase of 53.10%; net cash flow from operating activities was 3.423 billion yuan, a year-on-year increase of 30.61%.
As for the reasons for the growth of both revenue and net profit, Haohai Biotechnology said that as the domestic new crown pneumonia epidemic has been effectively controlled, the impact of the epidemic on business activities has gradually weakened, and the revenue of each product line has achieved substantial growth.
On the other hand, in addition to the performance growth, the overall gross profit margin of Haohai Biotechnology has dropped from 74.91% in 2020 to 72.13%.
Copyright Notice
1This article is an original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, excerpting, copying or creating mirror images, etc. Violators will be held accountable.
3Copyright cooperation telephone: 021-60900099.